CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Net Income

Bottom-line profit after all expenses, interest, and taxes.

CG Oncology, Inc. Common stockNASDAQ: CGON

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income remains negative

Q3 FY2026 net income was -$56.89M, compared with -$43.81M a year earlier. Trailing-twelve-month net income was -$237.46M.

Context

  • Net income amounted to 3985.0% of revenue in FY2025, down 3744.5 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$235.51M (-46.3%) for the fiscal year ending Dec 2026, a step up from the -82.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$56.89M+28.0% QoQ
Last fiscal yearDec 2025
-$161M-82.9% YoY
LTMSep 2026
-$237.46M-56.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.9%-55.0%-25.1 pp
1 year-82.9%-46.3%+36.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(161M) USD
Year-over-year change
-82.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 net income of -$237.46M is the 2nd highest of the 3 companies compared; the peer median is -$621.44M.
  • Its year-over-year change of -56.8% is the 2nd highest of 3, against a peer median of -107.3%.
  • Net income amounts to 3851.1% of revenue for CGON, versus a peer median of 351.3%.
CGON Competitors Peer median
Net Income for CGON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
URGNUroGen Pharma Ltd.LTM Mar 2026-$133.23M +3.8%—94.8%
CGONCG Oncology, Inc. Common stockLTM Sep 2026-$237.46M -56.8%—3851.1%
IBRXImmunityBio, Inc.LTM Sep 2026-$1.11B -218.3%—607.8%
Peer median (excluding CGON) -$621.44M-107.3%—351.3%

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.36M191K204K1.14M4.04M
Cost of Revenue10K15K45.75M82.1M4.65M
Gross Profit10.35M176K(45.55M)(80.96M)(607K)
Gross Margin99.9%92.1%-22327.5%-7108.3%-15.0%
Research & Development18.32M29.03M45.75M82.1M116.64M
Selling, General & Admin4.64M6.39M9.9M33.7M73.53M
Operating Expenses22.95M35.42M9.9M33.7M190.17M
Depreciation & Amortization10K15K17K32K1.45M
EBITDA(12.38M)(35.43M)(48.59M)(88.01M)(159.55M)
EBITDA Margin-119.5%-18548.2%-23818.6%-7726.7%-3949.3%
Operating Income(12.61M)(35.25M)(55.45M)(114.67M)(190.77M)
Operating Margin-121.7%-18453.4%-27180.9%-10067.3%-4722.1%
Interest Income006.9M26.62M29.93M
Interest Expense451K1K000
Other Income / Expenses(233K)(197K)6.84M26.63M29.78M
Income Before Tax(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Pre-Tax Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
Income Tax Expense00000
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Net Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
EPS (Basic)(0.28)(0.66)(1.02)(1.41)(2.08)
EPS (Diluted)(0.28)(0.66)(1.02)(1.41)(2.08)
Weighted Avg Shares66.64M66.64M66.64M62.5M77.3M
Weighted Avg Shares (Diluted)66.64M66.64M66.64M62.5M77.3M

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.